EUVIMEDEUVIMED entdecken
Crossref

Research progress of non-monoamine antidepressants

Huan Zhang, Bo Wang, Xiaohua Cao

Stress and Brain · 2021

DOI: 10.26599/sab.2021.9060002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stress and Brain, 2021. Verfasst von Huan Zhang und 2 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 110 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Major depressive disorder (MDD) is a recurring mental illness that has brought severe physical and psychological burdens to people around the world and caused heavy medical and economic burdens on society. For many years, the monoamine hypothesis based on the first- and second-generation antidepressants have been developed and put into clinical use, but the traditional monoamine antidepressants have a series of problems, such as poor targeting, strong side effects, and slow onset. The emergence of non-monoamine antidepressants such as ketamine, scopolamine, and brexanolone has injected new impetus into the development of long-silent antidepressants. They have the characteristics of fast onset, low toxicity, fewer side effects, and a better response rate to treatment-resistant depression (TRD). This review will discuss the characteristics, mechanisms, advantages, and remaining problems of non-monoamine antidepressants, and provide recommendations for future clinical and scientific research.

Zitieren

APA

Zhang, H., Wang, B., & Cao, X. (2021). Research progress of non-monoamine antidepressants. Stress and Brain. https://doi.org/10.26599/sab.2021.9060002

Vancouver

Zhang H, Wang B, Cao X. Research progress of non-monoamine antidepressants. Stress and Brain. 2021. doi:10.26599/sab.2021.9060002

BibTeX
@article{Zhang2021,
  author = {Zhang, Huan and Wang, Bo and Cao, Xiaohua},
  title = {Research progress of non-monoamine antidepressants},
  journal = {Stress and Brain},
  year = {2021},
  doi = {10.26599/sab.2021.9060002}
}
Kostenlos starten →